Products

Eisai Group has expanded the main figures of its contribution from the current "patients and their families" to "patients and the people in the daily living domain." With the desire to empower patient and the people in the daily living domain to “realize their fullest life”, we aim to evolve into an hhceco (hhc concept + ecosystem) company by creating solutions based on science and data in the fields of neurology and oncology, where unmet medical needs are extremely high and where our group has the greatest strength, and by building an ecosystem through collaboration with other industries and groups.

Eisai is committed to maximizing value for patients by developing additional formulations and expanding indications of our global brands: Halaven®, Lenvima®,  Fycompa® and Dayvigo®. In January 2023, Eisai Group's most important product, lecanemab (U.S. brand name Leqembi™), a treatment for Alzheimer's disease, received Accelerated Approval in the United States, and we are further expediting our efforts to obtain regulatory approval and expand access in other countries around the world.

In the neurology area, our in-house discovered and developed antiepileptic drug Fycompa® is approved as an adjunctive therapy for partial-onset seizures in over 75 countries. It is also approved for use as a monotherapy and for adjunctive use in the treatment of partial onset seizures (with or without secondarily generalized seizures) in patients 4 years of age and older in Japan, and China. In addition, Fycompa is approved as an adjunctive therapy for primary generalized tonic-clonic seizures in over 70 countries. The insomnia treatment Dayvigo® has been approved for the treatment of insomnia in over 15 countries.

In the oncology area, our in-house discovered and developed anticancer agent Halaven has been approved for use in the treatment of breast cancer in over 85 countries and also for use in the treatment of malignant soft tissue sarcoma in over 80 countries. Lenvima, another anticancer agent discovered and developed in-house, has been approved for use in the treatment of thyroid cancer in over 80 countries. Lenvima has also been approved for use in the treatment of hepatocellular carcinoma in over 80 countries. It has also been approved for use in the treatment of thymic carcinoma in Japan. It has been approved as combination therapy with everolimus for use in the treatment of renal cell carcinoma (second line) in over 60 countries. Finally, Lenvima has been approved for use in the treatment of renal cell carcinoma (first line) in combination with pembrolizumab in over 45 countries. (In Europe, the product name for this indication is Kisplyx®.) In addition, it has been approved for use in the treatment of endometrial carcinoma in combination with pembrolizumab in over 45 countries renal cell carcinoma in combination with pembrolizumab in over 35 countries including in Japan, the United States, and countries in Europe and in Asia. (In Europe, the product name for this indication is Kisplyx®.)

*The U.S. rights to Fycompa were transferred to Catalyst Pharmaceuticals, Inc. on January 25, 2023.